Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $15.50.

VTYX has been the subject of several analyst reports. Wall Street Zen upgraded Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Wednesday, November 5th. Oppenheimer raised their price objective on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Canaccord Genuity Group upped their target price on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC purchased a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $9,707,000. Vanguard Group Inc. boosted its holdings in Ventyx Biosciences by 19.2% in the third quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock valued at $11,725,000 after acquiring an additional 607,725 shares in the last quarter. Marshall Wace LLP bought a new stake in Ventyx Biosciences in the second quarter valued at $5,129,000. Vestal Point Capital LP increased its position in Ventyx Biosciences by 2.5% during the 3rd quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock valued at $6,376,000 after purchasing an additional 50,000 shares during the period. Finally, Millennium Management LLC raised its holdings in Ventyx Biosciences by 17.5% in the 3rd quarter. Millennium Management LLC now owns 1,651,794 shares of the company’s stock worth $5,137,000 after purchasing an additional 246,040 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors.

Ventyx Biosciences Price Performance

VTYX opened at $9.38 on Tuesday. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $10.55. The firm has a market capitalization of $669.36 million, a PE ratio of -6.25 and a beta of 1.22. The company’s 50-day moving average is $6.52 and its 200 day moving average is $3.87.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.13. As a group, analysts expect that Ventyx Biosciences will post -2.09 EPS for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.